[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcutaneous-vagal-nerve-stimulation-tvns\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcutaneous-vagal-nerve-stimulation-tvns":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100640586","effects-of-transcutaneous-vagus-nerve-stimulation-in-parkinsons-disease-100640586",false,"NCT07588191","Effects of Transcutaneous Vagus Nerve Stimulation in Parkinson´s Disease","Effects of Transcutaneous Stimulation of the Auricular Branch of the Vagus Nerve in Parkinson´s Disease","tVNS_PD","Inclusion Criteria:\n\n* Being a member of the Association or be interested in joining;\n* Idiopathic PD diagnosis, stages 2-3 according to the Hoehn \\& Yahr scale; confirmed by neurologist\n* Ability to walk independently for at least 1 minute ant turn 180° without assistance;\n* Exhibiting symptoms of hypokinetic dysarthria;\n* On stable dopaminergic therapy for at least 1 month prior to the experiment\n\nExclusion Criteria:\n\n* Any contraindication for taVNS (e.g., ear lesions, pacemakers, defibrillators, or other electronic devices)\n* Previous vagotomy or previous application of electrical stimulation to the ear or brain, or treatment with high-intensity focused ultrasound (HIFU)\n* Voice or speech disorders caused by other medical conditions\n* MoCA score below 21\n* Psychotic symptoms or hallucinations; a diagnosis of psychiatric illness\n* Systolic blood pressure above 160 mm Hg, and diastolic blood pressure above 100 mm Hg\n* Inability to attend sessions;\n* Concomitant neurological, orthopaedic, cardiac, respiratory or active medical\u002Foncological condition that would affect participation","ALL",{"count":19,"type":20},46,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to determine whether electrical stimulation of the ear, when combined with physical and speech therapy, can improve symptoms in subjects diagnosed with Parkinson´s disease, by comparing two different application sites.\n\nEach subject will undergo an initial in-person screening and provide consent before participating in the study.\n\nThe main questions to answer are:\n\n* Does transcutaneous electrical nerve stimulation (tVNS) in the ear paired with physical and speech therapy improve speech and voice-related problems, airway protection, salivation, and swallowing?\n* Does tVNS paired with physical and speech therapy improve tremor, walking speed, and balance in people with PD?\n* Does tVNS paired with physical and speech therapy improve heart rate and heart rate variability in people with PD?\n* Do its effects persist at 8 weeks?\n\nParticipants will:\n\nAttend 12 rehabilitation sessions over 4 weeks (three per week). During each session, participants received either active or sham tVNS, accompanied by speech therapy (once per week), physical therapy (once per week), or conducted alone (once per week).\n\nUndergo speech, voice, swallowing, respiratory, gait, balance, tremor, heart rate variability, and cognitive testing, as well as questionnaires regarding the quality of life, before and after treatment.\n\nReturn for a follow-up visit eight weeks after therapy to check how long the effects last.",[26,27],"Transcutaneous Vagal Nerve Stimulation (tVNS)","Parkinson Disease (PD)",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"transcutaneous electrical nerve stimulation","Vagus Nerve","Parkinson Disease","Speech Therapy","Physical Therapy Modalities","Deglutition","Tremor","Posture","Gait","Quality of Life","cognition","cough","Sialorrhea","Xerostomia","Heart Rate","voice disorders","Ear","RECRUITING","2026-05-15",{"date":49,"type":50},"2026-05-19","ACTUAL",{"date":52,"type":20},"2026-05",{"date":54,"type":20},"2026-11",{"name":56,"class":57},"Universidade da Coruña","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":58},"100624083","effect-of-vagus-nerve-stimulation-on-pain-intensity-nerve-conduction-studies-and-functional-outcomes-in-diabetic-peripheral-neuropathy-patients-100624083","NCT07405021","Effect of Vagus Nerve Stimulation on Pain Intensity, Nerve Conduction Studies and Functional Outcomes in Diabetic Peripheral Neuropathy Patients","Inclusion Criteria\n\n* Thirty patients diagnosed with diabetic neuropathy of both genders.\n* Age range between 45 and 60 years.\n* Presence of numbness and\u002For pain in the feet with no other identifiable cause.\n* Pain characterized as stabbing, electric shock-like, or burning in nature.\n* Presence of glove-stocking sensory changes and abnormal sensations in the distal lower limbs.\n* Ability to ambulate independently without assistance.\n* Patients under full medical control.\n* Hemoglobin A1c levels ranging from 6.5% to 7%.\n* History of diabetes mellitus for more than 5 years.\n\nExclusion Criteria\n\n* Implantation of cardiac pacemakers or other electrical stimulation devices.\n* Presence of sinus bradycardia, sick sinus syndrome, or other cardiac arrhythmias.\n* Lumbar radiculopathy.\n* Psychiatric or mental disorders or history of seizures.\n* Visual or auditory impairments or tremors affecting balance.\n* Presence of other neuromuscular disorders.\n* Foot deformities or active foot ulcers.\n* History of lower limb surgical operations.","45 Years","60 Years",{"count":68,"type":20},40,[23],"To evaluate the efficacy of vagus nerve stimulation in reducing neuropathic pain, symptom severity, electrophysiological studies and functional outcomes in patients with diabetic peripheral neuropathy.",[26,72],"Diabetic Polyneuropathy","2026-02-09",{"date":75,"type":50},"2026-02-12",{"date":77,"type":50},"2026-01-01",{"date":79,"type":20},"2026-04-01",{"name":81,"class":57},"Cairo University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":58},"100603067","the-effect-of-transcutaneous-vagal-nerve-stimulation-tvns-on-cerebral-vasospasm-secondary-to-aneurysmal-subarachnoid-hemorrhage-100603067","NCT07131696","The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Provision of signed and dated informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female\n* 18-65 years of age\n* Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage\n* Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage\n* For females of reproductive potential: negative pregnancy test at time of treatment.\n* Plan to undergo standard of care treatment and follow-up\n\nExclusion Criteria:\n\n* Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)\n* Does not provide consent\n* Posterior circulation aneurysmal subarachnoid hemorrhage\n* Initial aneurysm treatment after post bleed day 1","18 Years","65 Years",{"count":91,"type":20},10,[23],"The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down of normal arteries in the days following rupture - remains incredibly challenging to treat.1,2 Current drugs and minimally invasive surgical therapies are helpful, yet woefully insufficient. Symptomatic cerebral vasospasm afflicts about 30% of aneurysmal subarachnoid hemorrhage patients and nearly half will go on to suffer a stroke, despite aggressive medical care.1-3 The autonomic nervous system is a balance between sympathetic (fight or flight) and parasympathetic (rest and digest) influence with sympathetic overactivity and inflammation shown to play an important role in the development and severity of cerebral vasospasm.4,5,17-20 Prior studies of autonomic nervous system neuromodulation highlight its promise as a promising potential avenue to improve morbidity and mortality from CVS in aSAH.6-15 Despite progress, continued high levels of CVS morbidity and mortality stress the urgent need for exploration of neuromodulation therapy.\n\nIn this proposal, the study team will modulate the autonomic nervous system function in aSAH patients using transcutaneous vagal nerve stimulation (tVNS). tVNS involves placement of a stimulation electrode on the external ear to non-invasively stimulate a branch of the vagal nerve and increase parasympathetic influence. This device has FDA approval for epilepsy and cluster headache.\n\nThe study hypothesis is that neuromodulation of the autonomic nervous system with tVNS (increasing parasympathetic influence) reduces sympathetic overactivity and inflammation in aSAH resulting in decreased morbidity of CVS.",[95,96,26,97],"Aneurysmal Subarachnoid Hemorrhage","Vasospasm, Cerebral","Endovascular Treatment",[99,100,101],"CVS","aSAH","tVNS","NOT_YET_RECRUITING","2025-08-12",{"date":105,"type":50},"2025-08-20",{"date":107,"type":20},"2026-09",{"date":109,"type":20},"2028-09",{"name":111,"class":57},"Marshall Holland"]